D-cyclins repress apoptosis in hematopoietic cells by controlling death receptor fas and its ligand FasL

Developmental Cell

Volumn 30, Issue 3, 2014, Pages 255-267

  Choi, YoonJong ^a,b   Saez, Borja ^c,d,e   Anders, Lars ^a,f   Hydbring, Per ^a,b   Stefano, Joanna ^a,b   Bacon, Nickolas A ^a,b   Cook, Colleen ^c,d,e   Kalaszczynska, Ilona ^a,i   Signoretti, Sabina ^h   Young, Richard A ^f,g   Scadden, David T ^c,d,e   Sicinski, Piotr ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d HARVARD STEM CELL INSTITUTE   (United States)

^e Harvard University   (United States)

^f WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN D2; CYCLIN D3; DEATH RECEPTOR; FAS ANTIGEN; FAS LIGAND; TRANSCRIPTION FACTOR E2F1;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BONE MARROW; CELL SURVIVAL; CONTROLLED STUDY; GENE CONTROL; GENE REPRESSION; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; STEM CELL;

MAMMALIA; MUS;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CASPASE 8; CELL CYCLE; CELL PROLIFERATION; CYCLIN D1; CYCLINS; FAS LIGAND PROTEIN; HEMATOPOIETIC STEM CELLS; LIGANDS; MICE; MICE, KNOCKOUT;

EID: 84905719128     PISSN: 15345807     EISSN: 18781551     Source Type: Journal    
DOI: 10.1016/j.devcel.2014.06.015     Document Type: Article

References (34)

1. Adachi M., Suematsu S., Kondo T., Ogasawara J., Tanaka T., Yoshida N., Nagata S. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat. Genet. 1995, 11:294-300.
2. Anders L., Ke N., Hydbring P., Choi Y.J., Widlund H.R., Chick J.M., Zhai H., Vidal M., Gygi S.P., Braun P., Sicinski P. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 2011, 20:620-634.
3. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
4. Caserta T.M., Smith A.N., Gultice A.D., Reedy M.A., Brown T.L. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis 2003, 8:345-352.
5. Chen D., Pacal M., Wenzel P., Knoepfler P.S., Leone G., Bremner R. Division and apoptosis of E2f-deficient retinal progenitors. Nature 2009, 462:925-929.
6. Choi Y.J., Sicinski P. Unexpected outcomes of CDK4/6 inhibition. Oncotarget 2013, 4:176-177.
7. Choi Y.J., Li X., Hydbring P., Sanda T., Stefano J., Christie A.L., Signoretti S., Look A.T., Kung A.L., von Boehmer H., Sicinski P. The requirement for cyclin D function in tumor maintenance. Cancer Cell 2012, 22:438-451.
8. Chong J.L., Wenzel P.L., Sáenz-Robles M.T., Nair V., Ferrey A., Hagan J.P., Gomez Y.M., Sharma N., Chen H.Z., Ouseph M., et al. E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells. Nature 2009, 462:930-934.
9. DeGregori J., Johnson D.G. Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis. Curr. Mol. Med. 2006, 6:739-748.
10. Deshpande A., Sicinski P., Hinds P.W. Cyclins and cdks in development and cancer: a perspective. Oncogene 2005, 24:2909-2915.
11. Diehl J.A. Cycling to cancer with cyclin D1. Cancer Biol. Ther. 2002, 1:226-231.
12. Fleming H.E., Janzen V., Lo Celso C., Guo J., Leahy K.M., Kronenberg H.M., Scadden D.T. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal invivo. Cell Stem Cell 2008, 2:274-283.
13. Fry D.W., Harvey P.J., Keller P.R., Elliott W.L., Meade M., Trachet E., Albassam M., Zheng X., Leopold W.R., Pryer N.K., Toogood P.L. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 2004, 3:1427-1438.
14. Fu M., Wang C., Li Z., Sakamaki T., Pestell R.G. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 2004, 145:5439-5447.
15. Gurumurthy S., Xie S.Z., Alagesan B., Kim J., Yusuf R.Z., Saez B., Tzatsos A., Ozsolak F., Milos P., Ferrari F., et al. The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. Nature 2010, 468:659-663.
16. Hsieh J.-K., Fredersdorf S., Kouzarides T., Martin K., Lu X. E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev. 1997, 11:1840-1852.
17. Iaquinta P.J., Lees J.A. Life and death decisions by the E2F transcription factors. Curr. Opin. Cell Biol. 2007, 19:649-657.
18. Kozar K., Ciemerych M.A., Rebel V.I., Shigematsu H., Zagozdzon A., Sicinska E., Geng Y., Yu Q., Bhattacharya S., Bronson R.T., et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell 2004, 118:477-491.
19. Kühn R., Schwenk F., Aguet M., Rajewsky K. Inducible gene targeting in mice. Science 1995, 269:1427-1429.
20. Lukas J., Parry D., Aagaard L., Mann D.J., Bartkova J., Strauss M., Peters G., Bartek J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995, 375:503-506.
21. Malumbres M., Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 2009, 9:153-166.
22. Malumbres M., Sotillo R., Santamaría D., Galán J., Cerezo A., Ortega S., Dubus P., Barbacid M. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004, 118:493-504.
23. Musgrove E.A., Caldon C.E., Barraclough J., Stone A., Sutherland R.L. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 2011, 11:558-572.
24. Neuman E., Flemington E.K., Sellers W.R., Kaelin W.G. Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter. Mol. Cell. Biol. 1994, 14:6607-6615.
25. Puyol M., Martín A., Dubus P., Mulero F., Pizcueta P., Khan G., Guerra C., Santamaría D., Barbacid M. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010, 18:63-73.
26. Rossi D.J., Seita J., Czechowicz A., Bhattacharya D., Bryder D., Weissman I.L. Hematopoietic stem cell quiescence attenuates DNA damage response and permits DNA damage accumulation during aging. Cell Cycle 2007, 6:2371-2376.
27. INK4a-independent mechanisms. Mol. Cell. Biol. 2007, 27:4273-4282.
28. Sherr C.J., Roberts J.M. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004, 18:2699-2711.
29. Sicinski P., Donaher J.L., Geng Y., Parker S.B., Gardner H., Park M.Y., Robker R.L., Richards J.S., McGinnis L.K., Biggers J.D., et al. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 1996, 384:470-474.
30. Strasser A., Jost P.J., Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009, 30:180-192.
31. Trikha P., Sharma N., Opavsky R., Reyes A., Pena C., Ostrowski M.C., Roussel M.F., Leone G. E2f1-3 are critical for myeloid development. J.Biol. Chem. 2011, 286:4783-4795.
32. Trimarchi J.M., Lees J.A. Sibling rivalry in the E2F family. Nat. Rev. Mol. Cell Biol. 2002, 3:11-20.
33. Wilson A., Laurenti E., Oser G., van der Wath R.C., Blanco-Bose W., Jaworski M., Offner S., Dunant C.F., Eshkind L., Bockamp E., et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 2008, 135:1118-1129.
34. Zou X., Ray D., Aziyu A., Christov K., Boiko A.D., Gudkov A.V., Kiyokawa H. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev. 2002, 16:2923-2934.